AGM Statement and Proxy Voting Results (0909I)

TIDMATD

RNS Number : 0909I

Asterand PLC

08 June 2011

 
 For Immediate Release   8 June 2011 
 

Asterand plc

AGM Statement and Proxy Voting Results

Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery research, today held its Annual General Meeting ("AGM") at 10:00 (BST), in London.

During the meeting, Mr. Martyn Coombs, Asterand's CEO, provided an overview of the Company's business and future strategy and, Robert Coleman PhD DSc, a leading drug discovery consultant, gave a short presentation titled "The use of human tissue". www.asterand.com.

Also at the AGM, all of the resolutions set out in the Notice of Meeting sent to Shareholders as part of the Report and Financial Statements for the year ended 31 December 2010 were passed, save for resolution 10.

Proxy votes on the resolutions were as follows:

 
                                        For 
                                     (including 
       Ordinary Resolutions        discretionary)    Against     Vote Withheld 
----  -------------------------  ----------------  -----------  -------------- 
       To receive and adopt the 
        Report and 
 1.     Accounts                    58,508,772         512            240 
----  -------------------------  ----------------  -----------  -------------- 
       To receive and adopt the 
       Directors' report on 
 2.    remuneration                 47,298,921      11,190,067      20,536 
----  -------------------------  ----------------  -----------  -------------- 
       To re-elect Jill Force 
 3.    as a Director                58,489,976        9,308         10,240 
----  -------------------------  ----------------  -----------  -------------- 
       To re-elect Robert 
 4.    Salisbury as a Director      58,485,227        9,308         14,989 
----  -------------------------  ----------------  -----------  -------------- 
       To re-elect Jonathan 
 5.    Fleming as a Director        47,313,428      1,751,834      9,444,262 
----  -------------------------  ----------------  -----------  -------------- 
       To re-appoint 
       PricewaterhouseCoopers 
 6.    LLP as Auditors              58,502,583          0            6,941 
----  -------------------------  ----------------  -----------  -------------- 
       To amend the Company's 
 7.    articles of association      58,490,535        4,000         14,989 
----  -------------------------  ----------------  -----------  -------------- 
       That the Company's 
       memorandum of 
       association, being 
       deemed to form part of 
       the Articles, be 
 8.    amended                      58,490,535        4,000         14,989 
----  -------------------------  ----------------  -----------  -------------- 
       Issue of shares by the 
 9.    Directors                    42,738,770      15,751,514      19,240 
----  -------------------------  ----------------  -----------  -------------- 
       Disapplication of 
 10.   pre-emption rights           42,738,258      15,747,277      23,989 
----  -------------------------  ----------------  -----------  -------------- 
       Notice of general 
 11.   meetings                     58,499,284        10,000          240 
----  -------------------------  ----------------  -----------  -------------- 
 

- Ends -

Contacts:

 
 Asterand plc 
 Martyn Coombs, Chief Executive   Tel: + 44 (0) 1763 211 600 / + 1 (313) 
  Officer                          263-0960 
 John Stchur, Chief Financial     As above 
  Officer 
 
 Buchanan Communications 
 Lisa Baderoon / Mark Court       Tel: [phone] 
  / 
  Isabel Podda 
 
 Daniel Stewart & Company plc 
 Antony Legge                     Tel: [phone] 
 

About ASTERAND

Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the market.

For more information, go to www.Asterand.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGMFPMJTMBMMBLB